Binge eating disorder is one of the most common eating disorders, but despite that, it remains hard for people to find medications that would be efficient and, at the same time, not harmful to health. That is why the latest research about the development of medications that could help reduce binge eating is of special importance.
In the Neuroscience News study, the focus is on a recently published research review by researchers from University College London (UCL) regarding drugs known as GLP-1 receptor agonists that are already prescribed for treating diabetes and obesity but may influence the symptoms associated with binge eating as well. The problem raised by the researchers concerns the possible effects of the physical health drugs on the symptoms related to psychological problems.
Physiological Response and Psychological Impact of Binge Eating
Binge eating disorder (BED) Remission following recent initiation of treatment with GLP1 receptor agonists in patients with binge eating disorder (BED). GLP1 stands for glucagon-like peptide-1, a gut-derived hormone that regulates appetite, blood sugar, and the sensation of satiety. Registered dietitian and nutritionist researcher for instinctive advancement containing creatures experiencing obesity as a result. Published online October 5, 2022. This includes the following (APPEAL): GLP1 receptor agonists (GLP1RAs), blockbuster medications that mimic the effects of GLP1, which helps to reduce appetite and antagonistic food intake, leading to successful fat loss as well.
In BED, loss of control is harmfully entwined with the pleasure-related processes that motivate cravings and compulsive overeating via activated reward pathways. As BED is not only a disorder of appetite but also involves emotional and neurological factors, a holistic treatment approach must consider medication for appetite regulation (for example, GLP1 receptor agonists) alongside local targets in the brain’s reward systems to address this complex clinical problem.
Read More: What Are Eating Disorders?
Meta-analysis
The study published on Neuroscience News was a systematic review, not a clinical trial. Instead, UCL scientists compiled and assessed information from a wide range of studies, small pilot studies, case reports, and preclinical studies of GLP-1 RAs, such as liraglutide, semaglutide, and dulaglutide, for the treatment of binge eating and bulimia disorders.
Specifically, the reviewers asked what three things about this population of generally adult patients with BED or BN (many who were overweight/obese) taking a GLP-1 RA, for which binge frequencies, weights, and psychiatric concerns were measured; they wanted to know about GLP1s. Do GLP-1s lead to a reduced frequency of binge and/or loss-of-control episodes? Did they aid in the reduction of secondary symptoms, such as weight and/or diabetes?
Read More: Bulimia Nervosa: Decoding the Intricacies of Binge and Purge
Impact of binge eating disorder
The review’s papers consistently showed GLP-1 RAs lessened common symptoms of BED, such as frequency of binge episodes and losing the ability to control one’s eating. Several study authors also noted a decrease in body weight and improvements in metabolic factors, such as blood sugar, a valuable outcome, given that individuals with BED and BN often struggle with obesity and/or diabetes.
The review also documented improvements in psychological and behavioural factors, such as reductions in food craving and emotional eating, as well as lowered scores on questionnaires about binge severity. Crucially, the review pointed out that GLP1RAs tended to have fewer psychiatric side effects, such as mood swings or addictive potential, than several other current drugs for binge eating.
Author’s interpretation
The study authors suggest these results are an early yet optimistic indicator that GLP1RAs might represent a new pharmacologic approach for BED and BN through both metabolic and neurobiological mechanisms. “They know GLP1 receptors are expressed in brain regions involved in energy homeostasis and reward; therefore, these agents may not only create a sensation of satiety faster but also reduce the reward and craving aspects that contribute to overeating.”
The authors temper their optimism with caution. Most available trials to date are small and short-term, without proper blinding of participants or researchers, so they’ll need much larger placebo-controlled trials in people with eating disorders before they know the drug’s actual effectiveness and long-term safety. In expert commentary accompanying GLP-1 and eating disorders, authors cite “promise and caution”; GLP-1RAs could fill a big gap, but they should be used wisely, preferably in conjunction with psychotherapy, not as a cure-all.
Conclusion
The take-home message of the papers is that in many cases the core of the problems related to eating is a malfunction of our ancient brain systems, whether they’re regulated by the pleasure/reward centres of our brain or by signals from the food in our gut. GLP1 receptor agonists are the first class of medication to directly target these systems, and the results of preliminary studies are promising for a new way of treating both overeating and undereating that goes beyond merely addressing depression, weight, or individual food type preferences, although further research is still needed.
References +
- Neuroscience News. (2026b, July 16). GLP-1s reduce binge eating symptoms. Neuroscience News. https://neurosciencenews.com/glp1-agonists-binge-eating-31067/
- Eating Disorder Hope. (2023). Eating disorder hotlines for 24/7 crisis help. In Eating Disorder Hope. https://www.eatingdisorderhope.com/treatment-for-eating-disorders/eating-disorder-hotlines
- Moiz, A., Filion, K. B., Tsoukas, M. A., Yu, O. H. Y., Peters, T. M., & Eisenberg, M. J. (2025). Mechanisms of GLP-1 receptor agonist-induced weight loss: A review of central and peripheral pathways in appetite and energy regulation. The American Journal of Medicine, 138(6). https://doi.org/10.1016/j.amjmed.2025.01.021
